8,089 results on '"Arthritis, psoriatic"'
Search Results
2. A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
3. Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
4. COMFI - a COMbined Fatigue Intervention (COMFI)
5. A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (TRILOGY)
6. A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)
7. Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)
8. A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)
9. A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)
10. Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
11. A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
12. Psoriatic Arthritis Study of Izokibep
13. A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
14. Impact of Air Pollution on the Course of Inflammatory Rheumatism
15. Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response (IZAR-2)
16. Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (IZAR-1)
17. A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
18. A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE VITAL)
19. Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
20. Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)
21. A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
22. A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)
23. Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
24. Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
25. WORK-ON Vocational Rehabilitation for People with Inflammatory Arthritis (WORK-ON)
26. Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis. (OPTIMA)
27. Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis (NOR-SPRINT)
28. Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)
29. Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis (KRXeljanzJIA)
30. Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment (AgAIN)
31. An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
32. Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
33. Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity (RAISE)
34. A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
35. A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)
36. Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST)
37. Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
38. Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)
39. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
40. A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
41. A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
42. Stronger Together Psoriatic Arthritis Wellness Study
43. Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
44. Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)
45. A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)
46. A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
47. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)
48. Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database (FLYWAY)
49. A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)
50. IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT (IMPACT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.